Cervical cancer is the fourth most common cancer in women. According to the World Health Organization, there were around 604,000 new cases and 342,000 deaths in 2020.
The Serum Institute of India (SII), the world’s largest vaccine producer, has developed the country’s first cervical cancer vaccine, the company and the government confirmed Thursday.
The WHO reported 604,000 new cases and 342,000 deaths from cervical cancer in 2020. 90% of new cases and deaths worldwide have occurred in low and middle-income countries.
Two HPV varieties, 16 and 18, cause at least 70% of cervical cancers, and India’s Department of Biotechnology said the Indian vaccination would work on types 16 and 18, as well as 6 and 11.
Merck and GSK produce HPV vaccines.
The vaccine will be available in India and later globally in a few months. It will be priced between 200 and 400 rupees ($2.51-$5.03), and the company will generate 200 million doses in two years.
The vaccination will be injected twice in 9–14-year-olds and three times in 15–26-year-olds....